High mortality in patients with Mycobacterium avium complex lung disease: a systematic review

Abstract

BackgroundThe incidence of nontuberculous mycobacterial (NTM) pulmonary disease caused by Mycobacterium avium complex (MAC) in apparently immune-competent people is increasing worldwide. We performed a systematic review of the published literature on five-year all-cause mortality in patients with MAC lung disease, and pooled the mortality rates to give an overall estimate of five-year mortality from these studies.MethodsWe systematically reviewed the literature up to 1st August 2017 using PubMed® and ProQuest Dialog™ to search Medline® and Embase® databases, respectively. Eligible studies contained > 10 patients with MAC, and numerical five-year mortality data or a treatment evaluation for this patient group. Mortality data were extracted and analysed to determine a pooled estimate of all-cause mortality.ResultsFourteen of 1035 identified studies, comprising 17 data sets with data from a total of 9035 patients, were eligible. The pooled estimate of five-year all-cause mortality was 27% (95% CI 21.3–37.8%). A high degree of heterogeneity was observed (I2 = 96%). The mortality in the data sets varied between 10 and 48%. Studies predominantly including patients with cavitary disease or greater comorbidity reported a higher risk of death. Patients in Asian studies tended to have a lower mortality risk. Predictors of mortality consistent across studies included male sex, presence of comorbidities and advanced patient age.ConclusionsDespite high heterogeneity, most studies in patients with MAC pulmonary disease document a five-year all-cause mortality exceeding 25%, indicating poor prognosis. These findings emphasise the need for more effective management and additional prospective mortality data collection.Electronic supplementary materialThe online version of this article (10.1186/s12879-018-3113-x) contains supplementary material, which is available to authorized users.

Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey

“…Studies exploring the impact of NTM-LD on mortality have recently been published, showing that NTM-LD is associated with an increased risk of death irrespective of other comorbidities. [16][17][18] Previous studies showed that patients with specific NTM-LD manifestations like cavitary disease 19 or specific NTM species like Mycobacterium xenopi 20 have a higher mortality risk. Specific NTM-LD registries may provide further evidence on the respective risk factors in the future.…”

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease

“…Clinical symptoms of NTM lung disease vary in intensity between individuals and are generally non-specific, but they commonly include a chronic cough, sputum production, fatigue and weight loss. Disease progression can lead to deteriorating lung function (often with permanent damage) [ 3 ], reduced physical function and health-related quality of life [ 4 ], together with an increased risk of mortality [ 5 , 6 ].…”

The Rise of Non-Tuberculosis Mycobacterial Lung Disease

“…Fourthly, there are alarmingly high death rates in patients following diagnosis with NTM lung infection. A systematic review showed a 5 years mortality showed 27% in Europe, 35% in the US and 33% in Asia (118). Predictors of high mortality included male gender, presence of comorbidities, and fibro cavitary disease.…”